Real life experiences with biosimilars in multiple sclerosis – 1 learning hour (certified by ParadigMS)

About this e-learning

Welcome to our e-learning on “Real-Life Experiences with Biosimilars in Multiple Sclerosis”.

This e-learning module explores the scientific, regulatory, and clinical aspects of biosimilars in Multiple Sclerosis (MS), with a particular focus on biosimilar natalizumab. Through two expert-led presentations, the course combines regulatory foundations with real-world clinical experience, addressing key questions neurologists face when integrating biosimilars into routine practice.

In the first presentation, Jelena Drulovic provides an overview of biosimilars, their regulatory approval pathway, and the evidence supporting their use in MS. The second presentation, by Tjalf Ziemssen, focuses on real-life experience with biosimilars, including switching strategies, safety monitoring, and patient communication.

This course offers practical, evidence-based guidance to support informed clinical decision-making and optimize patient care.

Certificate

Participants will gain a ParadigMS Certificate upon completion.

Once you confirmed you participated, you will be able to download your Certificate of Participation from ‘Your Account‘.

How to confirm your participation: Complete this ‘e-learning’ (it includes one section and one exam).

Please note that this webinar has not been submitted by ParadigMS to the EACCME board for CME Accreditation. It is Certified by ParadigMS.

Learning objectives

Jelena Drulovic – Biosimilars in Multiple Sclerosis: scientific and regulatory foundations

This presentation focuses on the principles underpinning biosimilars, their development and regulatory evaluation, and the clinical evidence supporting their use in MS. It aims to clarify common misconceptions and provide a solid scientific basis for clinical adoption.

Learning Objectives:

• Understand what biosimilars are and how they differ from generic medicines.
• Explain the regulatory approval process for biosimilars, including the “totality of evidence” concept.
• Review the clinical and pharmacological evidence supporting biosimilarity in MS therapies.
• Assess the scientific rationale for extrapolation of indications in biosimilars.
• Address common concerns and misconceptions related to biosimilar use in clinical practice.

Tjalf Ziemssen – Real-life experience with biosimilars in MS care

This presentation addresses the practical implementation of biosimilars in routine MS care, with a focus on switching from reference biologics, safety monitoring, and patient-related considerations. Real-world data and clinical experience are used to illustrate best practices and challenges.

Learning Objectives:

• Review real-world evidence on the efficacy and safety of biosimilars in MS.
• Discuss practical considerations when switching patients from reference biologics to biosimilars.
• Understand safety monitoring requirements, including JC virus testing and PML risk assessment.
• Recognize the impact of the nocebo effect and the importance of effective patient communication.
• Apply shared decision-making strategies to support patient confidence and adherence.

The course also includes a dedicated Q&A session, where faculty address clinically relevant questions and expand on key topics discussed during the presentations.

The course was organized with the financial support of Sandoz.

Sandoz has not been involved in the elaboration of the presentations.